Ani Pharmaceuticals (ANIP) Revenue (2010 - 2026)

Ani Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $266.0 million for Q2 2026.

• In Q2 2026, Revenue rose 25.87% year-over-year to $266.0 million; the TTM figure through Jun 2026 stood at $978.4 million (up 30.9% YoY), while the FY2025 annual figure was $883.4 million, up 43.78% from the prior year.
• Revenue came in at $266.0 million for Q2 2026 at Ani Pharmaceuticals, up from $237.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $266.0 million in Q2 2026 to a low of $64.5 million in Q1 2022.
• Average Revenue over 5 years is $155.8 million, with a median of $137.7 million recorded in 2024.
• Year-over-year, Revenue soared 65.62% in 2023 and advanced 12.52% in 2024.
• Over 5 years, Revenue stood at $94.2 million in 2022, then surged by 39.71% to $131.7 million in 2023, then soared by 44.75% to $190.6 million in 2024, then rose by 29.64% to $247.1 million in 2025, then rose by 7.68% to $266.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $266.0 million in Q2 2026, $237.5 million in Q1 2026, and $247.1 million in Q4 2025.